Paresh Soni, M.D., Ph.D.

Chief Medical Officer

Paresh Soni joined Albireo in September 2016 as Chief Medical Officer. Dr. Soni has more than 25 years of clinical drug development and academic medical experience. Most recently, he served as Vice President, Global Medical Sciences at Alexion Pharmaceuticals, a global rare disease biopharma company. Prior to Alexion, Dr. Soni served as Senior Vice President, Head of Development at Amarin Corporation where he was responsible for the development and regulatory approval of Vascepa® for elevated triglycerides. He began his pharmaceutical career at Pfizer, holding various positions of increasing responsibility. Dr. Soni is an internist and gastroenterologist. He completed his medical training at the University of Natal in South Africa and a research fellowship at the Division of Hepatology, Royal Free Hospital School of Medicine, London. He has authored or co-authored more than 50 scientific papers in peer-reviewed journals, in addition to numerous abstracts.

Team members

Ron Cooper

President and Chief Executive Officer

Martha (Muffy) Carter

Chief Regulatory Officer

Jason Duncan

General Counsel

Per-Göran Gillberg, Ph.D., Prof.

Vice President, Development and Co-Founder

Jan Mattsson, Ph.D.

Chief Operating Officer and Co-Founder

Tom Shea

Chief Financial Officer

Paresh Soni, M.D., Ph.D.

Chief Medical Officer

Kristina Torfgård, Ph.D.

Vice President, Global Project Head